Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD)
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Genetics and epigenetics play a key role in the development of several diseases, including nonalcoholic fatty liver disease (NAFLD). Family studies demonstrate that first degree relatives of patients with NAFLD are at a much higher risk of the disease than the general population. The development of the Genome Wide Association Study (GWAS) technology has allowed the identification of numerous genetic polymorphisms involved in the evolution of diseases (e.g., PNPLA3, MBOAT7). On the other hand, epigenetic changes interact with inherited risk factors to determine an individual’s susceptibility to NAFLD. Modifications of the histones amino-terminal ends are key factors in the maintenance of chromatin structure and gene expression (cAMP-responsive element binding protein H (CREBH) or SIRT1). Activation of SIRT1 showed potential against the physiological mechanisms related to NAFLD. Abnormal DNA methylation represents a starting point for cancer development in NAFLD patients. Besides, the evaluation of circulating miRNA profiles represents a promising approach to assess and non-invasively monitor liver disease severity. To date, there is no approved pharmacologic therapy for NAFLD and the current treatment remains weight loss with lifestyle modification and exercise. In this review, the status of research into relevant genetic and epigenetic modifiers of NAFLD progression will be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Treatment of NAFLD with diet, physical activity and exercise
Romero-Gómez, M., Zelber-Sagi, S., & Trenell, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.016 · Cited by 1,347
Kozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234 · cited 2×
“In experimental models, silencing of TM6SF2 reduces secretion of very-low-density lipoproteins (VLDLs) and causes a predisposition to retention of triglycerides (TGs) in hepatic lipid droplets and fatty liver [37,38].”
BackgroundEpigenetics: a molecular link between environmental factors and type 2 diabetes
Ling, C., & Groop, L. (2009) · Diabetes · doi:10.2337/db09-1003 · Cited by 617 · cited 1×
“It has been described that aberrant histone modifications promote the development of insulin resistance and, consequently, NAFLD [44].”
BackgroundPiscaglia, F., Svegliati‐Baroni, G., Barchetti, A., Pecorelli, A., Marinelli, S., Tiribelli, C., Bellentani, S., & on behalf of the HCC‐NAFLD Italian Study Group (2016) · Hepatology · doi:10.1002/hep.28368 · Cited by 604
Pirola, C. J., Fernández Gianotti, T., Castaño, G. O., Mallardi, P., San Martino, J., Mora Gonzalez Lopez Ledesma, M., Flichman, D., Mirshahi, F., Sanyal, A. J., & Sookoian, S. (2015) · Gut · doi:10.1136/gutjnl-2014-306996 · Cited by 564 · cited 1×
“miR-122 Lipid metabolism, carcinogenesis [65] miR-192 NAFLD progression [66] miR-34a, miR-16 Lipid metabolism [67] miR-21, miR-34a Lipid metabolism [68] miR-1290, miR-27b-3p and miR-192-5p Several (panel) [64] miR-301a-3p, miR-34a-5p and miR-375 Several (biomarkers) [69] miR-182 Fibrogenesis [70] miR-155 Inflammatory…”
BackgroundLiu, Y.-L., Patman, G. L., Leathart, J. B. S., Piguet, A.-C., Burt, A. D., Dufour, J.-F., Day, C. P., Daly, A. K., Reeves, H. L., & Anstee, Q. M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.02.030 · Cited by 549 · cited 2×
“Numerous studies have validated this relationship [22,23], and new findings have been made, such as its relationship to ALT [24] serum levels and the full spectrum of NAFLD, including simple steatosis, steatohepatitis, cirrhosis and hepatocellular carcinoma [25,26], as well as systemic disorders more frequent in these…”
BackgroundDongiovanni, P., Petta, S., Maglio, C., Fracanzani, A. L., Pipitone, R., Mozzi, E., Motta, B. M., Kaminska, D., Rametta, R., Grimaudo, S., et al. (2015) · Hepatology · doi:10.1002/hep.27490 · Cited by 533 · cited 2×
“[39] have shown that TM6SF2 E167K variation is associated with NASH, hepatocellular ballooning, and necroinflammation in humans.”
BackgroundNonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus
Targher, G., Lonardo, A., & Byrne, C. D. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.173 · Cited by 397
Cited by
Metabolic Syndrome: Updates on Pathophysiology and Management in 2021
Fahed, G., Aoun, L., Bou Zerdan, M., Allam, S., Bou Zerdan, M., Bouferraa, Y., & Assi, H. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020786 · Cited by 1,441
High Levels of SIRT1 Expression as a Protective Mechanism Against Disease-Related Conditions
Elibol, B., & Kilic, U. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00614 · Cited by 171
“This modulation is mostly occurred through the deacetylation of metabolic regulators (46).”
BackgroundXiong, Y., Peng, Q., Cao, C., Xu, Z., & Zhang, B. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18063242 · Cited by 53
Lee, Y.-S., Oh, S. M., Li, Q.-Q., Kim, K.-W., Yoon, D., Lee, M.-H., Kwon, D.-Y., Kang, O.-H., & Lee, D. Y. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44010029 · Cited by 30
“Hepatic lipid accumulation produces multiple signals that can alter the metabolism of glucose and lipids, which leads to the presence of intracellular fat vacuoles, in addition to a lack of the capability to perform the mitochondrial β-oxidation processes, development of proinflammatory mechanisms, and generation of o…”
Background
Metadata
- Authors
- Del Campo, J., Gallego-Durán, R., Gallego, P., & Grande, L.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-03-19
- Volume
- 19
- Issue
- 3
- Pages
- 911
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2792959572
- Cited by
- 147
- References
- 17
- FWCI
- 10.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD). https://app.cochat.ai/papers/10.3390/ijms19030911
- The paper
- Del Campo, J., Gallego-Durán, R., Gallego, P., & Grande, L. (2018). Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD). International Journal of Molecular Sciences. https://doi.org/10.3390/ijms19030911
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.